Press Releases

7/22/2009
FoldRx Pharmaceuticals Announces Positive Results from Pivotal Phase II/III Clinical Study of Tafamidis
FoldRx Pharmaceuticals, Inc. (FoldRx) today announced positive results from its pivotal Phase II/III clinical study of the company’s lead compound, tafamidis (Fx-1006A), in patients suffering from TTR amyloid polyneuropathy (ATTR-PN), a fatal orphan disease also known as Familial Amyloid Polyneuropathy (FAP).

6/9/2009
William Aliski Named FoldRx Chief Commercial Offiicer
FoldRx adds industry veteran William Aliski to the management team as Chief Commercial Officer and completes financing to advance program towards commercialization.

5/20/2009
FoldRx Takes Great Strides and Raises Over $18,000 for Cystic Fibrosis Research
FoldRx particpated in the Cystic Fibrosis Foundation's Great Strides Walk and raised over $18,000 for Cystic Fibrosis research and support.

2/26/2009
FoldRx to Raise Awareness of TTR Amyloidosis in Conjunction With NORD’s Rare Disease Day
FoldRx announced today that it will host a program at its company headquarters on Friday, February 27 to raise awareness of rare diseases, including Transthyretin Amyloidosis (ATTR).

11/11/2008
New Research of Amyloid Cardiomyopathy Fosters Better Understanding of Disease Progression
A recent study of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) has enabled a new understanding of the rare and fatal disease.

10/7/2008
FoldRx Announces Rapid Progress With Development Program For Lead Candidate
FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that enrollment is underway in an open-label Phase II clinical study with its lead drug candidate, Fx-1006A, for patients suffering from TTR Amyloid Cardiomyopathy (ATTR-CM).

7/8/2008
FoldRx Technology Enables Discovery of Novel Therapeutic Approach for Treating Cystic Fibrosis
Achievement of first milestone marks rapid progress in Cystic Fibrosis Foundation Therapeutics collaboration

8/13/2007
FoldRx and Cystic Fibrosis Foundation Therapeutics Announce $22 Million Collaboration
FoldRx will utilize its yeast-based discovery platform to discover and develop novel therapeutics aimed at treating cystic fibrosis

5/29/2007
Foldrx Announces Its Phase II/III Clinical Study With Lead Clinical Candidate
Fx-1006A is being evaluated as a disease-modifying agent in the treatment of Familial TTR Amyloidosis

6/22/2006
FoldRx announces study defining role of key protein and biological pathway implicated in Parkinson's disease
FoldRx Pharmaceuticals, Inc. announced today the publication of a study by Susan Lindquist and collaborators that defines the role of a key protein and biological pathway implicated in Parkinson disease.

5/30/2006
FoldRx Pharmaceuticals closes $43 Million Series B financing
FoldRx Pharmaceuticals, Inc., a development-stage biotechnology company focused on protein misfolding diseases, announced today that it has successfully raised $43 million in a Series B financing.

10/12/2005
FoldRx announces the initiation of a Phase 1 study with First Clinical Candidate
FoldRx Pharmaceuticals, Inc. (FoldRx) announced today that it has initiated a Phase I clinical study with its lead candidate, Fx-1006A, a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).

9/27/2005
FoldRx Pharmaceuticals, Inc. appoints Christoph M. Adams, Ph.D., as Chief Business Officer
FoldRx Pharmaceuticals, Inc. (FoldRx), announced today that it has appointed Christoph M. Adams, Ph.D., as Chief Business Officer. Dr. Adams brings to FoldRx extensive experience in business and commercial development.

12/13/2004
FoldRx Pharmaceuticals, Inc. Closes on $16 Million Series A Round of Funding
FoldRx Pharmaceuticals, Inc., a discovery and development company focusing on first in class disease-modifying small molecule therapeutics to treat diseases of protein misfolding and aggregation, today announced that the company has successfully completed a $16 million Series A round of financing.